
Sign up to save your podcasts
Or
This week’s episode of “The Top Line,” is the final part of a three-part series diving into the latest advancements in cell and gene therapy manufacturing.
In this episode, Fierce Pharma’s Fraiser Kansteiner is joined by Bruce Levine, Ph.D., who is the co-inventor of Kymriah and the Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania. He’s also joined by executives from CGT technology provider ScaleReady and regenerative cell therapy developer CellProthera.
They dive into novel production approaches discussed earlier in this series, with a special focus on CAR-T therapies.
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.
3.8
88 ratings
This week’s episode of “The Top Line,” is the final part of a three-part series diving into the latest advancements in cell and gene therapy manufacturing.
In this episode, Fierce Pharma’s Fraiser Kansteiner is joined by Bruce Levine, Ph.D., who is the co-inventor of Kymriah and the Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania. He’s also joined by executives from CGT technology provider ScaleReady and regenerative cell therapy developer CellProthera.
They dive into novel production approaches discussed earlier in this series, with a special focus on CAR-T therapies.
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.
1,753 Listeners
381 Listeners
1,034 Listeners
991 Listeners
1,784 Listeners
375 Listeners
122 Listeners
318 Listeners
171 Listeners
876 Listeners
88 Listeners
29 Listeners
147 Listeners
10 Listeners
51 Listeners